A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

NCT00524368 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

590

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus - Type 1

Interventions

DRUG: Darunavir (DRV)
DRUG: Ritonavir (rtv)

Sponsor

Tibotec Pharmaceuticals, Ireland